Stereotactic Radiosurgery for Perioptic Meningiomas: An International, Multicenter Study

BACKGROUND: Stereotactic radiosurgery (SRS) is increasingly used for management of perioptic meningiomas. OBJECTIVE: To study the safety and effectiveness of SRS for perioptic meningiomas. METHODS: From 12 institutions participating in the International Radiosurgery Research Foundation (IRRF), we retrospectively assessed treatment parameters and outcomes following SRS for meningiomas located within 3 mm of the optic apparatus. RESULTS: A total of 438 patients (median age 51 yr) underwent SRS for histologically confirmed (29%) or radiologically suspected (71%) perioptic meningiomas. Median treatment volume was 8.01 cm(3). Median prescription dose was 12 Gy, and median dose to the optic apparatus was 8.50 Gy. A total of 405 patients (93%) underwent single-fraction SRS and 33 patients (7%) underwent hypofractionated SRS. During median imaging follow-up of 55.6 mo (range: 3.15-239 mo), 33 (8%) patients experienced tumor progression. Actuarial 5-yr and 10-yr progression-free survival was 96% and 89%, respectively. Prescription dose of >= 12 Gy (HR: 0.310; 95% CI [0.141-0.679], P =.003) and single-fraction SRS (HR: 0.078; 95% CI [0.016-0.395], P =.002) were associated with improved tumor control. A total of 31 (10%) patients experienced visual decline, with actuarial 5-yr and 10-yr post-SRS visual decline rates of 9% and 21%, respectively. Maximum dose to the optic apparatus >= 10 Gy (HR = 2.370; 95% CI [1.086-5.172], P = .03) and tumor progression (HR= 4.340; 95% CI [2.070-9.097], P<.001) were independent predictors of post-SRS visual decline. CONCLUSION: SRS provides durable tumor control and quite acceptable rates of vision preservation in periopticmeningiomas. Margin dose of >= 12 Gy is associated with improved tumor control, while a dose to the optic apparatus of >= 10 Gy and tumor progression are associated with post-SRS visual decline.

Automated summary

SRS provides durable tumor control and acceptable rates of vision preservation in perioptic meningiomas. A prescription dose of >= 12 Gy is associated with improved tumor control, while a dose to the optic apparatus of >= 10 Gy and tumor progression are associated with post-SRS visual decline.